Aurinia Pharmaceuticals (AUPH) Revenue by Segment

Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability. This helps assess the company's strategic focus and potential areas of risk or opportunity.

Net Product Sales have become the primary, steadily compounding revenue engine—evidence of successful commercialization and market uptake—while License/Collaboration/Royalty remains episodic, producing large one‑off spikes that distort headline growth. The multi‑year acceleration into high‑tens of millions per quarter shifts Aurinia from milestone‑dependent to product‑driven; the modest Q1 2026 pullback looks like timing or seasonality rather than structural weakness, so investors should model future revenue around product momentum and treat license income as unpredictable upside.